CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionOperating margin is 41.2%, higher than 95% of its Biotechnology peers (median -23.8%)
- FinancialsAltman Z-Score 6.34: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.79%Below 5Y avg (0.83%)
Annual Rate
CNY 0.06Paid annual
Payout Ratio
71.4%Moderate
Last Ex-Dividend
Jul 17, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.93BCNY1.03B · vs all stocks (USD)
Trailing P/E
59.64xvs Biotechnology peers
Revenue (TTM)
794.80MCNY118.19M · vs all stocks (USD)
Profit Margin
13.59%vs Biotechnology peers
Beta
-0.1840xvs all stocks
52-Week Change
-29.95%vs all stocks
Market Capitalization
6.93BCNY1.03B · vs all stocks (USD)
Enterprise Value
5.91BCNY878.67M · vs all stocks (USD)
Trailing P/E
59.64xvs Biotechnology peers
Forward P/E
19.88xvs Biotechnology peers
Price to Sales (TTM)
8.72xvs Biotechnology peers
Price to Book (MRQ)
2.91xvs Biotechnology peers
Enterprise to Revenue
7.43xvs Biotechnology peers
Enterprise to EBITDA
30.58xvs Biotechnology peers
Gross Margin
62.39%vs Biotechnology peers
Profit Margin
13.59%vs Biotechnology peers
Operating Margin
41.25%vs Biotechnology peers
Return on Assets (TTM)
2.35%vs Biotechnology peers
Return on Equity (TTM)
4.56%vs Biotechnology peers
Revenue (TTM)
794.80MCNY118.19M · vs all stocks (USD)
Revenue per Share (TTM)
0.9880CNYUpdated Aug 21, 2026Quarterly Revenue Growth
0.70%vs Biotechnology peers
Gross Profit (TTM)
410.11MCNY60.99M · vs all stocks (USD)
EBITDA (TTM)
235.94MCNY35.09M · vs all stocks (USD)
Net Income (TTM)
108.03MCNY16.07M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-18.90%vs Biotechnology peers
Operating Cash Flow (TTM)
120.43MCNY17.91M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-105.87MCNY-15.74M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0640CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.79%vs all stocks
5-Year Average Dividend Yield
0.83%vs all stocks
Payout Ratio
71.43%vs Biotechnology peers
Revenue
792.76MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
368.56MCNYFY2025 · Dec 31, 2025Gross Profit
424.20MCNYFY2025 · Dec 31, 2025Operating Income
138.63MCNY20.62M · vs all stocks (USD)
Pre-tax Income
137.90MCNYFY2025 · Dec 31, 2025Income Tax Expense
7.33MCNYFY2025 · Dec 31, 2025Net Income
130.57MCNYFY2025 · Dec 31, 2025EBIT
145.99MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
235.94MCNYFY2025 · Dec 31, 2025Research & Development
167.89MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
58.70MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.98MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
23.88MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.09MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1600CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
816.06MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
816.06MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
130.57MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
129.85MCNYFY2025 · Dec 31, 2025Free Cash Flow
25.52MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.18BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
130.57MCNYFY2025 · Dec 31, 2025Other Non-cash Items
28.70MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-9.12MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-20.29MCNYFY2025 · Dec 31, 2025Capital Expenditures
-104.34MCNYFY2025 · Dec 31, 2025Other Investing Activity
45.91MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-58.42MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
505.18MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-320.36MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-90.62MCNYFY2025 · Dec 31, 2025Other Financing Charges
-43.75MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
50.45MCNYFY2025 · Dec 31, 2025Shares Outstanding
830.30MSharesUpdated Aug 21, 2026Float Shares
372.45MSharesUpdated Aug 21, 2026% Held by Insiders
57.89%vs all stocks
% Held by Institutions
3.17%vs all stocks
Total Cash (MRQ)
1.15BCNY171.55M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.40CNYUpdated Aug 21, 2026Total Debt (MRQ)
486.22MCNY72.31M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2054xvs Biotechnology peers
Current Ratio (MRQ)
2.64xvs Biotechnology peers
Book Value per Share (MRQ)
2.87CNYUpdated Aug 21, 2026Total Assets
3.09BCNY458.81M · vs all stocks (USD)
Total Current Assets
1.82BCNYFY2025 · Dec 31, 2025Total Liabilities
815.89MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.27BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
79.87MCNYFY2025 · Dec 31, 2025Total Current Liabilities
736.02MCNYFY2025 · Dec 31, 2025Cash
1.18BCNYFY2025 · Dec 31, 2025Cash Equivalents
41.55MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.22BCNYFY2025 · Dec 31, 2025Other Short-term Investments
3.94MCNYFY2025 · Dec 31, 2025Accounts Receivable
142.03MCNYFY2025 · Dec 31, 2025Inventory
398.30MCNYFY2025 · Dec 31, 2025Accounts Payable
270.10MCNYFY2025 · Dec 31, 2025Short-term Debt
412.40MCNYFY2025 · Dec 31, 2025Other Current Liabilities
98.29KCNYFY2025 · Dec 31, 2025Long-term Debt
44.25MCNYFY2025 · Dec 31, 2025Common Stock (Book)
830.30MCNYFY2025 · Dec 31, 2025Retained Earnings
903.47MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.27BCNY337.48M · vs all stocks (USD)
Treasury Stock
50.01MCNYFY2025 · Dec 31, 202552-Week Low
7.15CNYUpdated Aug 21, 202652-Week High
12.51CNYUpdated Aug 21, 202652-Week Change
-29.95%vs all stocks
Beta
-0.1840xvs all stocks
50-Day MA
8.05CNYUpdated Aug 21, 2026200-Day MA
9.38CNYUpdated Aug 21, 2026Avg 10-Day Volume
10.04MSharesUpdated Aug 21, 2026Avg 30-Day Volume
9.94MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.1400CNYUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 41.2%, higher than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: 0.41Industry median: -0.24Industry P95: 0.38Peers compared: 197
Financial Health
Altman Z-Score 6.34: safe zoneNotable
Altman Z-Score: 6.34
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Jiangsu Aidea Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Highfine Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Animal Husbandry Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xiangyu Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Yahong Meditech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cronos Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medincell SA
Tier 1ProductionApproval-Gated PipelineRule
Avalo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Haiyao Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Edan Instruments Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Jiangsu Hengxing New Materials Co., Ltd.
1 interpretationPrice Below Mean With Profitability And Equity
Wintao Communications Co.
1 interpretationPrice Below Mean With Profitability And Equity
Wuxi Honghui New Materials Co., Ltd.
1 interpretationPrice Below Mean With Profitability And Equity